JP2013249268A - Composition for improving fluidity of blood - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition for improving fluidity of blood.SOLUTION: A composition for improving fluidity of blood includes astaxanthin and red ginseng. The red ginseng is preferably a red ginseng extract. Astaxanthin is preferably a Haematococcus alga extract containing astaxanthin.

Description

  The present invention relates to a composition for improving blood fluidity.

  Astaxanthin is the main component of the red pigment produced by Haematococcus algae, and is listed as a “non-medicine” (an ingredient that is not determined to be a pharmaceutical unless it has an indication of efficacy) in the amended category of drugs in November 2002. It was. Astaxanthin is now used in health foods and cosmetics, and its recognition is increasing.

  Astaxanthin has a strong antioxidant action, and further, various functions such as anti-inflammatory, anti-arteriosclerosis, anti-muscular fatigue, anti-eye strain, brain function improvement, blood flow improvement and the like are known (for example, Patent Document 1).

  On the other hand, red ginseng is known to have a vasodilatory action, a platelet aggregation inhibitory action, an erythrocyte deformability enhancing action, and the like. Red ginseng is different from ginseng because it contains components different from ginseng (Non-patent Document 1).

JP 2006-347927 A

16th revision Japanese Pharmacopoeia, page 1488

  The object of the present invention is to provide a composition for improving blood fluidity.

  The present invention is a composition for improving blood fluidity containing astaxanthin and red ginseng.

  The composition of the present invention has the advantage of improving blood fluidity.

FIG. 1 is a graph showing measurement results of systolic blood pressure of a control group, a red ginseng extract group, and an astaxanthin group. FIG. 2 is a graph showing measurement results of diastolic blood pressure of the control group, red ginseng extract group, and astaxanthin group. FIG. 3 is a graph showing measurement results of systolic blood pressure of a control group and a mixture group of red ginseng extract and astaxanthin. FIG. 4 is a graph showing measurement results of diastolic blood pressure of a control group and a mixture group of red ginseng extract and astaxanthin. FIG. 5 is a graph showing the results of the time taken to pass through a microcirculation model device for blood collected from rats of the control group, red ginseng extract group and astaxanthin group. FIG. 6 is a graph showing the results of time taken to pass through a microcirculation model device for blood collected from rats of a control group and a mixture group of red ginseng extract and astaxanthin.

  The present invention is a composition for improving blood fluidity containing astaxanthin and red ginseng. In addition, astaxanthin and red ginseng are known to have a slight blood flow improvement effect even when used alone, but if both are included, a superior blood fluidity can be obtained due to a synergistic effect. Moreover, the composition of this invention also has the effect | action which suppresses a blood pressure rise.

In the present invention, the red ginseng is a herbal medicine obtained by steaming ginseng (Panax ginseng CA Meyer) roots, and ginsenoside Rg ₁ (C ₄₂ H ₇₂ O ₁₄ : 801.01) 0.10% or more and ginsenoside Rb ₁ (C ₅₄ H ₉₂ O ₂₃ : 1109.29) 0.20% or more (see the 16th revision Japanese Pharmacopoeia). Examples of red ginseng include red ginseng powder, red ginseng extract (extracted liquid, concentrated extract, and dried powder after concentration of the extracted liquid), among which red ginseng extract is preferred. As the extract, for example, red ginseng (Japanese Pharmacopoeia) is pulverized into a powder, 30% ethanol aqueous solution is added, left at room temperature for 24 hours, and then insoluble matter can be removed by filtration. . As what concentrated the said extract, it can obtain by concentrating the said extract under reduced pressure, for example. The powder obtained by concentrating the extract and drying can be obtained, for example, by spray-drying a concentrate of the extract.

In the present invention, when the red ginseng is red ginseng powder, the ratio of the astaxanthin to the red ginseng powder is preferably astaxanthin: red ginseng powder (weight ratio) = 1: 50 to 5000, More preferably, it is 50-3500.
In the present invention, when the red ginseng is red ginseng extract (extract, concentrated extract, powder dried after concentrating the extract), it is used to obtain the astaxanthin and the red ginseng extract. The ratio of red ginseng (original drug substance) is preferably astaxanthin: red ginseng (original drug substance) (weight ratio) = 1: 50 to 5,000, more preferably 1:50 to 3,500.
In the present invention, when the red ginseng is red ginseng extract (powder obtained by concentrating the extract and dried), the content of the astaxanthin and the red ginseng extract (powder obtained by concentrating the extract and dried) is astaxanthin: Red ginseng extract (weight ratio) = 1: 13-1500 is preferable, and 1: 13-900 is more preferable.

  In the present invention, the astaxanthin is 3,3′-dihydroxy-β, β-carotene-4,4′-dione and has a stereoisomer. Specifically, three types of stereoisomers of (3R, 3'R) -astaxanthin, (3R, 3'S) -astaxanthin and (3S, 3'S) -astaxanthin are known. In the present invention, any one stereoisomer or a mixture of two or more stereoisomers may be used.

  In the present invention, unless otherwise specified, astaxanthin includes astaxanthin (free form) and / or an ester thereof. The ester of astaxanthin includes a monoester and / or a diester.

  Astaxanthin monoesters include lower saturated fatty acids, higher saturated fatty acids (eg, palmitic acid, stearic acid, etc.), lower unsaturated fatty acids, higher unsaturated fatty acids (eg, oleic acid, linoleic acid, linolenic acid, etc.), polyvalent Examples thereof include esters esterified with carboxylic acid, amino acid (glycine, alanine and the like), inorganic acid (phosphoric acid, sulfuric acid and the like), sugar, sugar fatty acid, glycerophosphoric acid and the like. Astaxanthin diesters include lower saturated fatty acids, higher saturated fatty acids (eg, palmitic acid, stearic acid, etc.), lower unsaturated fatty acids, higher unsaturated fatty acids (eg, oleic acid, linoleic acid, linolenic acid, etc.), polyvalent carboxylic acids Examples include diesters that are diesterified with the same or different types of acids selected from acids, amino acids (such as glycine and alanine), inorganic acids (such as phosphoric acid and sulfuric acid), sugars, sugar fatty acids, and glycerophosphoric acid.

  The astaxanthin is contained in shrimp, crab shellfish, salmon, fish such as Thailand, algae such as Haematococcus, yeasts such as red yeast Phaffia, and the like. In the present invention, the astaxanthin is preferably an astaxanthin-containing Haematococcus alga extract. Hematococcus algae is a kind of freshwater single-celled green algae, and has a diameter of about 20 μm and is wrapped in gelatine and has two flagella. Usually, it is a green algae, so it has a high chlorophyll content and is green, whereas it becomes cystic under starvation conditions such as nitrogen source deficiency and forms dormant spores with a high astaxanthin content. Therefore, the astaxanthin-containing Haematococcus alga means dormant spores.

  The composition for improving blood fluidity containing astaxanthin and red ginseng of the present invention includes, in addition to astaxanthin and red ginseng, excipients, binders, disintegrants, lubricants, stabilizers, dispersants, Additives such as flavoring agents and surfactants may be included. Examples of the surfactant include nonionic surfactants (sorbitan fatty acid esters, glycerin fatty acid esters, etc.), amphoteric surfactants (betaines, lecithin, etc.), anionic surfactants (alkyl sulfates, etc.) ) And cationic surfactants (alkyl ammonium salts and the like).

  This invention is a health food containing the composition for improving the blood fluidity containing the astaxanthin and red ginseng of this invention. As the health food, the composition may be processed into a liquid, powder, granule, tablet or the like. Alternatively, the composition may be encapsulated. As the capsule, for example, a gelatin capsule, a hydroxypropyl methylcellulose (HPMC) capsule, or the like can be used. The daily intake per adult of the composition (as a composition comprising astaxanthin and red ginseng) is, for example, 170 mg to 1000 mg, preferably 300 mg to 900 mg.

[Example 1]
About red ginseng extract and astaxanthin, alone or a mixture was administered to rats, and the effect on blood pressure and blood fluidity was confirmed.
<Test sample>
-Red ginseng extract: 30% ethanol aqueous solution (25 L) was added to powder (2.5 kg) of red ginseng (Japanese Pharmacopoeia) and left to stand at room temperature for 24 hours. Thereafter, the insoluble matter was removed by filtration, the obtained aqueous solution was concentrated to about 1 L under reduced pressure, and the concentrated solution was spray-dried to obtain 650 g of red ginseng extract powder. This red ginseng extract powder was used as red ginseng extract.

  Astaxanthin (composition): Astaxel (registered trademark) powder 20F (manufactured by Fuji Chemical Industry Co., Ltd.) was used. Astarille (registered trademark) powder 20F contains astaxanthin as a main component. The astaxanthin is a mixture of three stereoisomers of (3R, 3'R) -astaxanthin, (3R, 3'S) -astaxanthin and (3S, 3'S) -astaxanthin. The astaxanthin is a mixture of an ester form and a free form, and the ester form is an ester form of a higher fatty acid (palmitic acid, oleic acid, stearic acid, linoleic acid, linolenic acid), and Asteryl (registered trademark). The powder 20F contains 1.8% or more astaxanthin in terms of free form. Astaryl (registered trademark) powder 20F is a Haematococcus alga extract preparation.

  -Mixture of red ginseng extract and astaxanthin: The red ginseng extract (500 mg) and the astaxanthin (composition) (166.7 mg) were mixed to prepare a mixture of red ginseng extract and astaxanthin. Astaxanthin: Red ginseng extract in the mixture (weight ratio) = 3 mg: 500 mg = 1: 166.7. Moreover, astaxanthin: red ginseng (raw drug substance) (weight ratio) in the above mixture = 3 mg: 1923 mg = 1: 641.

<Measurement equipment>
・ Animal used: Spontaneously hypertensive rat (SHR)
・ Preliminary feed: General animal feed for animal experiments CE-2 (Nippon Claire Co., Ltd.) The raw materials used are protein source: soybean meal, white fish meal, yeast; fat source: germ, soybean oil; fiber source : Husma, defatted rice bran, alfalfa meal; carbohydrate sources: flour, corn, milo; vitamins: vitamins A, D ₃ , E, B ₁ , B ₂ , B ₆ , B ₁₂ , C, niacin, pantothenic acid, biotin, Folic acid, choline chloride, inositol; minerals: calcium carbonate, salt, iron sulfate, manganese sulfate, cobalt sulfate, calcium iodate).
・ Microcirculation model device (microchannel array): MC-FAN (Bloody6-4, Hitachi Haramachi Electronics Co., Ltd.)
・ Non-invasive automatic blood pressure measuring device: BP-98A-L (Softron Co., Ltd.)

<Dose of test sample>
Red ginseng extract: 500 mg / kg (animal weight)
Astaxanthin (composition): 166.7 mg / kg (animal body weight) (3 mg / kg (animal body weight) for astaxanthin)
Mixture of red ginseng extract and astaxanthin: red ginseng 500 mg / kg (animal weight) + astaxanthin (composition) 166.7 mg / kg (animal weight) (astaxanthin 3 mg / kg (animal weight))

<Experimental food and administration method>
Experimental diet: feed mixed with red ginseng extract, astaxanthin (composition), and a test sample corresponding to the dose of a mixture of red ginseng extract and astaxanthin.
Control diet: A feed that does not contain the test sample contained in the experimental diet.
The components of the experimental meal and the control meal are shown in Table 1. The amount of components described in the table is parts by weight.

* 1: Oriental Yeast Co., Ltd. * 2: Mineral mixture is calcium monohydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, salt, calcium lactate, iron citrate, magnesium sulfate, zinc carbonate, manganese sulfate And potassium iodide.
* 3: Vitamin mixture, vitamin _{A, D 3, E, K} 3, B 1, B 2, B 6, B 12, C, D- biotin, folic acid, nicotinic acid, inositol, choline chloride, para-aminobenzoic acid and Contains cellulose.

  Experimental or control diets were freely given to the animals used with saline. The group of animals fed the experimental diet (red ginseng extract, astaxanthin (composition), and a mixture of red ginseng extract and astaxanthin) and a control diet were classified into the red ginseng extract group, the astaxanthin group, and the mixed group of red ginseng extract and astaxanthin. , As well as the control group.

<Test method>
SHR male rats (4 weeks old) were bred for 2 weeks. Thereafter, the group was divided into 6 groups, and the experimental diet or the control diet was ingested for 3 weeks. During the intake of the experimental diet or the control diet, the blood pressure of the rats was measured once a week. Three weeks after the start of intake, blood was collected from the lower abdominal aorta of rats anesthetized with ether. The time taken for the collected blood (100 μL) to pass through the MC-FAN was measured. The passage time was converted using the passage time of physiological saline (100 μL) according to the following formula when the passage time of physiological saline was 12 seconds.

<Result>
[blood pressure]
The measurement results of the systolic blood pressure of the control group, red ginseng extract group, and astaxanthin group measured during the test period are shown in Table 2 and FIG. The measurement results of the diastolic blood pressure of the control group, red ginseng extract group, and astaxanthin group measured during the test period are shown in Table 3 and FIG. Table 4 and FIG. 3 show the measurement results of the systolic blood pressure of the control group and the mixture group of red ginseng extract and astaxanthin measured during the test period. The measurement results of the diastolic blood pressure of the control group and the mixture group of red ginseng extract and astaxanthin measured during the test period are shown in Table 5 and FIG.

  As shown in Tables 2 to 5 and FIGS. 1 to 4, in the mixture group of red ginseng extract and astaxanthin, a blood pressure increase inhibitory effect was confirmed from one week after ingestion. On the other hand, in the case of the red ginseng extract group and the astaxanthin group, an inhibitory effect on blood pressure was confirmed after 2 weeks. Therefore, the mixture group of red ginseng extract and astaxanthin was able to confirm an antihypertensive effect at an early stage as compared with the case of the red ginseng group and the astaxanthin group.

[Blood fluidity]
The time for each blood (100 μL) collected from the rats of the control group, red ginseng extract group and astaxanthin group to pass through the microcirculation model device was measured. The obtained results are shown in Table 6 and FIG. In addition, the time taken for blood (100 μL) collected from rats of the control group and the red ginseng extract and astaxanthin mixture group to pass through the microcirculation model device was measured. The obtained results are shown in Table 7 and FIG.

  As shown in Table 6 and FIG. 5, the red ginseng extract group and the astaxanthin group showed a reduction in blood passage time of 8.8 to 15.5% compared to the control group.

  As shown in Table 7 and FIG. 6, the mixture group of red ginseng extract and astaxanthin was found to have a 67.6% reduction in blood passage time compared to the control group. That is, it was confirmed that the blood passage time was significantly shortened compared with the red ginseng extract group and the astaxanthin group.

[Example 2]
Red ginseng extract (255 g) and astaxanthin (composition) obtained in Example 1 (Asteryl (registered trademark) oil 50F (manufactured by Fuji Chemical Industry Co., Ltd.) 60 g; containing 3 g astaxanthin), glycerin fatty acid ester (trade name) : Poem DO-100V, substance name: diglycerin monooleate, manufactured by Riken Vitamin Co., Ltd., surfactant, 10 g), glycerin (solvent, 185 g) and purified water (solvent, 90 g) are emulsified and mixed, resulting in a total of 600 g did. This was filled into HPMC capsules in an amount of 0.4 g to produce a health food.

[Example 3]
Red ginseng extract (5.1 kg) and astaxanthin (composition) obtained in Example 1 (Asteril (registered trademark) powder 20F (manufactured by Fuji Chemical Co., Ltd.) 3.3 kg, containing 60 g astaxanthin) and dextrin Forming agent, trade name: Paindex, manufactured by Matsutani Chemical Industry Co., Ltd., 11.6 kg) were mixed to make a total of 20 kg. This mixture was granulated using a fluid bed granulator (Flow coater, Freund Sangyo Co., Ltd.) to produce a granular health food.

  The composition of the present invention can also be applied to uses such as pharmaceuticals, health foods and health supplements.

Claims (5)

  A composition for improving blood fluidity, comprising astaxanthin and red ginseng.   The composition according to claim 1, wherein the red ginseng is red ginseng extract.   The composition according to claim 1 or 2, wherein the astaxanthin is an astaxanthin-containing Haematococcus alga extract. The red ginseng extract is a powder dried after concentrating the red ginseng extract,
4. The composition according to claim 2, wherein the content of the astaxanthin and the red ginseng extract is astaxanthin: red ginseng extract (weight ratio) = 1: 13 to 1500. 5.   The health food containing the composition in any one of Claims 1-4.

Images